3-phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 271-280

  Fyffe, Chanse ^a   Falasca, Marco ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

3 phosphoinositide dependent protein kinase 1; AGC protein kinases; Breast cancer therapy; Cell signaling; Oncogenic kinase; Phosphoinositide 3 kinase

Indexed keywords

2 O BENZYLINOSITOL 1,3,4,5,6 PENTAKISPHOSPHATE; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; GSK 2334470; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN SERINE THREONINE KINASE INHIBITOR; S6 KINASE; STAT3 PROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EVEROLIMUS; INOSITOL 1,3,4,5,6 PENTAKISPHOSPHATE; MESSENGER RNA; NATURAL PRODUCT; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1 INHIBITOR; TEMSIROLIMUS;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CHROMOSOME 16; COPY NUMBER VARIATION; DRUG POTENTIATION; DRUG TARGETING; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS INHIBITION; MIGRATION INHIBITION; NONHUMAN; PIK3CA GENE; PROTEIN PHOSPHORYLATION; SOMATIC MUTATION; TUMOR GROWTH; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CELL SURVIVAL; DOWN REGULATION; DRUG BINDING SITE; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; GROWTH REGULATION; METABOLIC REGULATION; PDPK1 GENE; REVIEW; SIGNAL TRANSDUCTION;

EID: 84884161634     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S35026     Document Type: Article

References (79)

1. Hutchinson L. Breast cancer: Challenges, controversies, breakthroughs. Nature Reviews Clinical Oncology 2010;7:669-670.
2. Hara K, Yonezawa KSakaue H et al., 1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc Natl Acad Sci U S A. 1994;91(16):7415-7419.
3. Wennström S, Hawkins P, Cooke F, et al. Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling. Curr Biol. 1994;4(5):385-393.
4. Okada T, Kawano Y, Sakakibara T, Hazeki O, Ui M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J Biol Chem. 1994;269(5):3568-3573.
5. Dudek H, Datta SR, Franke TF, et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 1997;275(5300): 661-665.
6. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 1997;385(6616):544-548.
7. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A. 1997;94(8):3627-3632.
8. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296(5573):1655-1657.
9. Fyffe C, Buus R, Falasca M. Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms.Curr Pharm Des. 2013;19(4):680-686.
10. Haslam RJ, Koide HB, Hemmings BA. Pleckstrin domain homology. Nature. 1993;363(6427):309-310.
11. Harlan JE, Hajduk PJ, Yoon HS, Fesik SW. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature. 1994;371(6493):168-170.
12. Lemmon MA, Falasca M, Schlessinger J, Ferguson K. Regulatory recruitment of signalling molecules to the cell membrane by pleckstrinhomology domains. Trends Cell Biol. 1997;7(6):237-242.
13. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol. 1997;7(4):261-269.
14. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature. 1995;376(6541): 599-602.
15. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279(5351):710-714.
16. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007;129(7):1261-1274.
17. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5): 283-296.
18. Oda K, Stokoe D, Taketani Y, McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65(23):10669-10673.
19. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
20. Samuels Y, Waldman T. Oncogenic mutations of PIK3CA in human cancers. Curr Top Microbiol Immunol. 2010;347:21-41.
21. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A. 2005;102(3):802-807.
22. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004;3(8): 772-775.
23. Falasca M, Maffucci T. Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J. 2012;443(3):587-601.
24. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol. 2010;11(5):329-341.
25. Edling CE, Selvaggi F, Buus R, et al. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res. 2010;16(20): 4928-4937.
26. Meadows SA, Vega F, Kashishian A, et al. PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2012;119(8):1897-1900.
27. Castillo JJ, Furman M, Winer ES. CAL-101: a phosphatidylinositol-3 kinase p110-delta inhibitor for the treatment of lymphoid malignancies. Expert Opin Investig Drugs. 2012;21(1):15-22.
28. Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603-3612.
29. Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117(2):591-594.
30. Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116(12):2078-2088.
31. Lin HJ, Hsieh FC, Song H, Lin J. Elevated phosphorylation and activation of PDK-1/AKT pathway in human breast cancer. Br J Cancer. 2005;93(12):1372-1381.
32. Vasudevan KM, Barbie DA, Davies MA, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell. 2009;16(1):21-32.
33. Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem. 2011;18(18):2763-2769.
34. Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol. 2010;11(1):9-22.
35. Wick MJ, Ramos FJ, Chen H, Quon MJ, Dong LQ, Liu F. Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop. J Biol Chem. 2003;278(44):42913-42919.
36. Currie RA, Walker KS, Gray A, et al. Role of phosphatidylinositol 3,4,5-trisphosphate in regulating the activity and localization of 3-phosphoinositide-dependent protein kinase-1. Biochem J. 1999; 337(Pt 3):575-583.
37. Masters TA, Calleja V, Armoogum DA, et al.Regulation of 3-phosphoinositide-dependent protein kinase 1 activity by homodimerization in live cells. Sci Signal. 2010;3(145):ra78.
38. Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol. 2004;15(2):161-170.
39. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997;15(4):356-362.
40. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-1947.
41. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/ Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A. 1999;96(4):1563-1568.
42. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet. 1998;19(4):348-355.
43. Qiu W, Schönleben F, Li X, et al. PIK3CA mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12(5):1441-1446.
44. Carén H, Fransson S, Ejeskär K, Kogner P, Martinsson T. Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br J Cancer. 2007;97(10):1416-1424.
45. Liu P, Morrison C, Wang L, et al. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis. 2012;33(7):1270-1276.
46. Dituri F, Mazzocca A, Lupo L, et al. PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. Int J Cancer. 2012;130(11):2505-2513.
47. Xie Y, Abel PW, Kirui JK, et al. Identification of upregulated phosphoinositide 3-kinase γ as a target to suppress breast cancer cell migration and invasion. Biochem Pharmacol. 2013;85(10): 1454-1462.
48. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2006;103(5):1289-1294.
49. Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol. 2005;15(20):1839-1846.
50. Pearn L, Fisher J, Burnett AK, Darley RL. The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood. 2007;109(10):4461-4469.
51. Bhola NE, Freilino ML, Joyce SC, et al. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012;11(6):1236-1246.
52. Fujiwara SKawano Y,Yuki H, et al., PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013;108(1):170-178.
53. Eser S, Reiff N, Messer M, et al. Selective requirement of PI3K/ PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell. 2013;23(3):406-420.
54. Tan J, Lee PL, Li Z, et al. B55β-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell. 2010;18(5):459-471.
55. Maurer M, Su TSaal LH, et al., 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res. 2009;69(15):6299-6306.
56. Nagashima K, Shumway SD, Sathyanarayanan S, et al. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem. 2011;286(8):6433-6448.
57. Finlay DK, Sinclair LV, Feijoo C, et al. Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. J Exp Med. 2009;206(11):2441-2454.
58. Pinner S, Sahai E. PDK1 regulates cancer cell motility by antagonising inhibition of ROCK1 by RhoE. Nat Cell Biol. 2008;10(2): 127-137.
59. Raimondi C, Chikh A, Wheeler AP, Maffucci T, Falasca M. A novel regulatory mechanism links PLCγ1 to PDK1. J Cell Sci. 2012;125(Pt 13): 3153-3163.
60. Muranen TA, Greco D, Fagerholm R, Kilpivaara O, Kämpjärvi K, Aittomäki K, Blomqvist C, Heikkilä P, Borg A, Nevanlinna H. Breast tumors from CHEK2 1100delC-mutation carriers: genomic landscape and clinical implications. Breast Cancer Res. 2011; 13(5):R90.
61. Choucair KA, Guérard KP, Ejdelman J, et al. The 16p13.3 (PDPK1) Genomic gain in prostate cancer: a potential role in disease progression. Transl Oncol. 2012;5(6):453-460.
62. Xie Z, Yuan H, Yin Y, Zeng X, Bai R, Glazer RI. 3-phosphoinositidedependent protein kinase-1(PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer. 2006;6:77.
63. Gagliardi PA, di Blasio LOrso F,et al.3-phosphoinositide-dependent kinase 1 controls breast tumor growth in a kinase-dependent but Aktindependent manner. Neoplasia. 2012;14(8):719-731.
64. Baxi SM, Tan W, Murphy ST, Smeal T, Yin MJ. Targeting 3 phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One. 2012;7(10):e48402.
65. Liu Y, Wang J, Wu M, et al. Down-regulation of 3-phosphoinositidedependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res. 2009;7(6): 944-954.
66. Fan R, Kim NG, Gumbiner BM. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proc Natl Acad Sci U S A. 2013;110(7):2569-2574.
67. Wang GM, Wong HY, Konishi H, et al. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Res. 2013;73(11): 3248-3261.
68. Wu J, Dauchy RT, Tirrell PC, et al. Light at night activates IGF-1R/ PDK1 signaling and accelerates tumor growth in human breast cancer xenografts. Cancer Res. 2011;71(7):2622-2631.
69. Medina JR. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1. J Med Chem. 2013;56(7):2726-2737.
70. Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. Chem Med Chem. 2008;3(12):1810-1838.
71. Falasca M, Chiozzotto D, Godage HY, et al. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer. 2010;102(1):104-114.
72. Najafov A, Sommer EM, Axten JM, Deyoung MP, Alessi DR. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Biochem J. 2011;433(2):357-369.
73. Iorns E, Lord CJ, Ashworth A. Parallel RNAi and compound screens identify the PDK1 pathway as a target for tamoxifen sensitization. Biochem J. 2009;417(1):361-370.
74. Falasca M. PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010;16(12):1410-1416.
75. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-AktmTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013;11(6):670-678.
76. Yardley DA. Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: rationale, clinical experience, and future directions. Breast Cancer (Auckl). 2013;7:7-22.
77. Najafov A, Shpiro N, Alessi DR. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J. 2012;448(2): 285-295.
78. Klement GL, Goukassian D, Hlatky L, Carrozza J, Morgan JP, Yan X. Cancer therapy targeting the HER2-PI3K pathway: potential impact on the heart. Front Pharmacol. 2012;3:113.
79. Finlay DK, Rosenzweig E, Sinclair LV, et al. PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells. J Exp Med. 2012;209(13):2441-2453.